Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Arcus Biosciences
Biotech
Gilead backs out of option to buy immunotherapy-focused Tizona
Gilead will not buy immunotherapy biotech Tizona Therapeutics, backing out of an option that the company paid $300 million for in 2020.
Max Bayer
Feb 6, 2024 7:15pm
Gilead stops phase 3 TIGIT trial, doubles down on other studies
Jan 30, 2024 8:09am
Arcus, Gilead drop A2R inhibitor in prostate cancer
Aug 7, 2023 11:00am
Gilead and Arcus' TIGIT combo continues to show signs of life
Jun 3, 2023 1:30pm
Gilead expands Arcus oncology pact into inflammatory disease
May 15, 2023 11:31am
Gilead's R&D spending spiked 25% in Q1
Apr 28, 2023 10:50am
